0.38
+0.0347(+10.03%)
Currency In USD
Address
11085 Torreyana Road
San Diego, CA 92121
United States of America
Phone
858 558 0708
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
December 16, 2020
| Name | Title | Pay | Year Born |
| Dr. Jay M. Short Ph.D. | Co-Founder, Chief Executive Officer & Chairman | 1.13M | 1958 |
| Mr. Christian J. Vasquez CPA | Chief Accounting Officer, Controller and Corporate Secretary | 408,745 | 1975 |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer | 654,588 | 1964 |
| Mr. Richard A. Waldron | Senior Vice President & Chief Financial Officer | 655,938 | 1954 |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development | 0 | N/A |
| Lisa M. Pelton | Accounting Manager | 0 | N/A |
| Ms. Sheri Lydick | Chief Commercial Officer | 0 | N/A |
| Ms. Susie Melody | Senior Vice President of Human Resources | 0 | N/A |
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research & Development | 0 | N/A |
| Ms. Monica Sullivan | Senior Vice President of Intellectual Property & Contracts | 0 | N/A |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.